Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07600736
PHASE2
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy
Sponsor: Actio Biosciences, Inc.
View on ClinicalTrials.gov
Summary
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
Official title: A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric and Young Adult Participants With KCNT1-Related Epilepsy
Key Details
Gender
All
Age Range
1 Month - 21 Years
Study Type
INTERVENTIONAL
Enrollment
55
Start Date
2026-05-18
Completion Date
2028-01
Last Updated
2026-08-07
Healthy Volunteers
No
Conditions
Interventions
DRUG
ABS-1230
Daily
DRUG
Placebo
Daily
Locations (1)
Northeast Regional Epilepsy Group
Hackensack, New Jersey, United States